Announcements
- GeneType and Stayhealthy Announce Landmark Distribution Agreement for Revolutionary Multi-Risk Test
- GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer
- GeneType and Humanise Health host “Know Your Risk” Event
- GTG and ‘Wellworks for You’ sign B2B sales & marketing deal covering 750 employer groups and 2 million U.S. employees
- Appendix 4C & Quarterly Business Update – March 2024
- Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
- Genetic Technologies Announces $2 Million Registered Direct Offering
- New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
- GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year
- GTG to pilot GeneType in Breast Screen centers across the U.S.
More ▼
Key statistics
On Thursday, Genetic Technologies Ltd (0A4N:LSE) closed at 1.91, 9.14% above its 52-week low of 1.75, set on May 29, 2024.
52-week range
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 1.91 |
Average volume | 2.86k |
---|---|
Shares outstanding | 4.41m |
Free float | 725.60k |
P/E (TTM) | -- |
Market cap | 8.84m USD |
EPS (TTM) | -1.17 USD |
Data delayed at least 15 minutes, as of May 30 2024 17:30 BST.
More ▼